COH Stock Overview
Cochlear Limited provides implantable hearing solutions for adults and children worldwide.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$223.85|
|52 Week High||AU$257.76|
|52 Week Low||AU$178.55|
|1 Month Change||10.73%|
|3 Month Change||3.40%|
|1 Year Change||-10.19%|
|3 Year Change||6.47%|
|5 Year Change||59.70%|
|Change since IPO||7,488.14%|
Recent News & Updates
The Returns On Capital At Cochlear (ASX:COH) Don't Inspire Confidence
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
A Look At The Fair Value Of Cochlear Limited (ASX:COH)
In this article we are going to estimate the intrinsic value of Cochlear Limited ( ASX:COH ) by projecting its future...
|COH||AU Medical Equipment||AU Market|
Return vs Industry: COH exceeded the Australian Medical Equipment industry which returned -17.2% over the past year.
Return vs Market: COH underperformed the Australian Market which returned -7.9% over the past year.
|COH Average Weekly Movement||4.1%|
|Medical Equipment Industry Average Movement||11.5%|
|Market Average Movement||10.6%|
|10% most volatile stocks in AU Market||17.5%|
|10% least volatile stocks in AU Market||4.7%|
Stable Share Price: COH is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: COH's weekly volatility (4%) has been stable over the past year.
About the Company
Cochlear Limited provides implantable hearing solutions for adults and children worldwide. It offers cochlear implant systems, sound processor upgrades, bone conduction systems, accessories, and other products. The company was founded in 1981 and is headquartered in Sydney, Australia.
Cochlear Fundamentals Summary
|COH fundamental statistics|
Is COH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|COH income statement (TTM)|
|Cost of Revenue||AU$408.70m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 19, 2022
|Earnings per share (EPS)||3.95|
|Net Profit Margin||16.51%|
How did COH perform over the long term?See historical performance and comparison
1.4%Current Dividend Yield
Is COH undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for COH?
Other financial metrics that can be useful for relative valuation.
|What is COH's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does COH's PE Ratio compare to its peers?
|COH PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
RHC Ramsay Health Care
SHL Sonic Healthcare
PME Pro Medicus
Price-To-Earnings vs Peers: COH is expensive based on its Price-To-Earnings Ratio (56.6x) compared to the peer average (53.9x).
Price to Earnings Ratio vs Industry
How does COH's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: COH is expensive based on its Price-To-Earnings Ratio (56.6x) compared to the Global Medical Equipment industry average (24.1x)
Price to Earnings Ratio vs Fair Ratio
What is COH's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||56.6x|
|Fair PE Ratio||34.7x|
Price-To-Earnings vs Fair Ratio: COH is expensive based on its Price-To-Earnings Ratio (56.6x) compared to the estimated Fair Price-To-Earnings Ratio (34.7x).
Share Price vs Fair Value
What is the Fair Price of COH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: COH (A$223.85) is trading above our estimate of fair value (A$197.08)
Significantly Below Fair Value: COH is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is lower than the current share price.
Discover undervalued companies
How is Cochlear forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COH's forecast earnings growth (10.9% per year) is above the savings rate (1.8%).
Earnings vs Market: COH's earnings (10.9% per year) are forecast to grow faster than the Australian market (6.2% per year).
High Growth Earnings: COH's earnings are forecast to grow, but not significantly.
Revenue vs Market: COH's revenue (8.6% per year) is forecast to grow faster than the Australian market (5.7% per year).
High Growth Revenue: COH's revenue (8.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COH's Return on Equity is forecast to be low in 3 years time (19.1%).
Discover growth companies
How has Cochlear performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COH has high quality earnings.
Growing Profit Margin: COH became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: COH's earnings have declined by 13.3% per year over the past 5 years.
Accelerating Growth: COH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: COH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (32.6%).
Return on Equity
High ROE: COH's Return on Equity (15%) is considered low.
Discover strong past performing companies
How is Cochlear's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: COH's short term assets (A$1.2B) exceed its short term liabilities (A$377.6M).
Long Term Liabilities: COH's short term assets (A$1.2B) exceed its long term liabilities (A$324.6M).
Debt to Equity History and Analysis
Debt Level: COH has more cash than its total debt.
Reducing Debt: COH's debt to equity ratio has reduced from 35.5% to 2.7% over the past 5 years.
Debt Coverage: COH's debt is well covered by operating cash flow (651.6%).
Interest Coverage: COH's interest payments on its debt are well covered by EBIT (51.1x coverage).
Discover healthy companies
What is Cochlear current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: COH's dividend (1.38%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.62%).
High Dividend: COH's dividend (1.38%) is low compared to the top 25% of dividend payers in the Australian market (6.24%).
Stability and Growth of Payments
Stable Dividend: COH is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.
Growing Dividend: COH is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: COH is not paying a notable dividend for the Australian market.
Cash Payout to Shareholders
Cash Flow Coverage: COH is not paying a notable dividend for the Australian market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dig Howitt (55 yo)
Mr. Diggory William Howitt, also known as Dig, BE (Hons), MBA has been President of Cochlear Limited since July 31, 2017 and its Chief Executive Officer and Managing Director since January 3, 2018. Mr. How...
CEO Compensation Analysis
Compensation vs Market: Dig's total compensation ($USD3.35M) is about average for companies of similar size in the Australian market ($USD3.99M).
Compensation vs Earnings: Dig's compensation has been consistent with company performance over the past year.
Experienced Management: COH's management team is seasoned and experienced (6.1 years average tenure).
Experienced Board: COH's board of directors are considered experienced (5.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cochlear Limited's employee growth, exchange listings and data sources
- Name: Cochlear Limited
- Ticker: COH
- Exchange: ASX
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: AU$14.724b
- Shares outstanding: 65.78m
- Website: https://www.cochlear.com
Number of Employees
- Cochlear Limited
- 1 University Avenue
- Macquarie University
- New South Wales
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/07 00:00|
|End of Day Share Price||2022/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.